Case Study: Medium Specialty Pharma – Revitalising Strategy by Overcoming Integrated Evidence Plan Exhaustion

The Challenge: Drowning in Process, Starving for Actionable Strategy – The "IEP Exhaustion" Syndrome

This specialty pharma was no stranger to the concept of Integrated Evidence Plans. They understood, in principle, the need to strategically align their evidence generation activities. However, their past experiences with IEP development, typically outsourced to large, traditional CROs, had left them with a profound sense of "IEP exhaustion."

The common pain points were all too familiar:

• Lengthy and Bureaucratic Processes: IEP development exercises dragged on for months, consuming significant internal resources and budget, with little tangible output to show for the extended effort.
  
  
• Static, Unwieldy Outputs: The end result was often a voluminous PowerPoint presentation – quickly outdated, difficult to navigate or update, and impractical as a day-to-day strategic tool.
  
  
• Failure to Align Global and Regional Needs: A critical issue for a company with a multi-regional footprint was the inability of these static IEPs to effectively bridge the gap between global strategic imperatives and the specific evidence needs of regional medical affairs and market access teams.
  
  
• Perceived Lack of Value: Consequently, internal teams increasingly viewed IEPs as a burdensome "tick-box" exercise mandated by leadership, rather than a useful tool that could genuinely shape strategy, simplify workflows, or drive impactful evidence generation. Strategic drift and sub-optimal resource allocation were real risks.
  
  
• No Clear Oversight for Leadership: Senior management lacked a clear, consolidated, and up-to-date dashboard view of evidence generation activities, priorities, and progress across their diverse portfolio, hampering effective strategic planning and resource allocation.

They desperately needed a way to revitalise their approach to evidence planning – one that was agile, genuinely useful, easy to update, and could provide clear, real-time strategic oversight.

The Inovia Bio Solution: A Fast, Dynamic, Platform-Driven IEP Approach

The specialty pharma engaged Inovia Bio, seeking a fresh perspective and a more effective solution to their evidence planning woes. Inovia Bio’s approach was designed to directly counter their previous frustrations:

1. Rapid, Value-Focused IEP Development: Leveraging the Inovia IEP platform and a streamlined, collaborative framework, Inovia Bio delivered a comprehensive and actionable IEP for key assets/TAs in an average of just 12 days – a stark contrast to the months-long sagas of the past. The focus was immediately on identifying high-impact evidence gaps and prioritising activities that would deliver tangible value.
   
   
2. A Living, Breathing Evidence Strategy: The core differentiator was the Inovia IEP platform itself. Instead of a static document, the IEP became a dynamic, cloud-based resource, providing a real-time view of evidence needs, ongoing projects, shifting priorities, and tactical plans. This ensured the IEP was always current and relevant.
   
   
3. Facilitating Global-Regional Alignment: The platform served as a single source of truth, accessible to both global and regional teams. This fostered better communication, transparency, and alignment on evidence generation priorities, ensuring that global strategies were effectively translated into regionally relevant tactics.
   
   
4. Dashboarding for Strategic Oversight: The Inovia IEP platform provided senior leadership with the intuitive dashboard views they craved, offering clear insights into evidence generation progress, resource allocation, and alignment with strategic goals across the portfolio.
   
   
5. Innovative Gap-Filling Strategies: Utilising RWE360 to explore diverse real-world data sources and Inovamine for rapid analytics, Inovia Bio was able to identify novel, efficient, and often accelerated ways to address critical evidence gaps identified during the IEP process, moving beyond conventional approaches.

"Using RWD360 allowed the company in this case study to have a complete, regulatory-grade landscape of every RWD asset relevant to their disease, as well as a landscape of KOLs, complete in less than a week"

The Impact: IEPs Transformed from Burden to Strategic Asset

The engagement with Inovia Bio fundamentally changed the specialty pharma’s relationship with Integrated Evidence Planning:

• Renewed Confidence in Strategic Planning: The speed, clarity, and actionable nature of Inovia Bio’s IEP process reinvigorated internal teams, transforming the IEP from a dreaded obligation into a valued strategic tool.
  
  
• Enhanced Agility and Responsiveness: The dynamic Inovia IEP platform allowed the company to adapt its evidence strategies quickly to changing market conditions, new data, or evolving scientific understanding.
  
  
• Improved Cross-Functional and Geographical Alignment: Teams now had a shared, real-time understanding of evidence priorities, leading to more cohesive and efficient execution of plans across the globe.
  
  
• Empowered Leadership: Senior management gained clear, up-to-date visibility into their entire evidence generation landscape, enabling more informed strategic decisions and better resource management across their CNS, oncology, and infectious disease portfolios.
  
  
• Significant Time and Cost Efficiencies: The rapid development process and the move away from cumbersome, static documents resulted in substantial savings in both time and direct costs associated with evidence planning and management.

The Inovia Advantage: Making Strategic Evidence Planning Work for Complex Portfolios

For medium-sized specialty pharma companies grappling with portfolio complexity and disillusioned by traditional IEP approaches, Inovia Bio offers a clear path forward:

• Platform-Driven Dynamism: Moving beyond static plans to live, adaptable evidence strategies.
• Speed to Value: Delivering actionable insights and plans in days, not months.
• Facilitating True Alignment: Providing tools that connect global strategy with regional execution.
• Actionable Insights, Not Just Reports: Focusing on practical, prioritised evidence generation tactics.

Inovia Bio helped this specialty pharma overcome its "IEP exhaustion", providing a sophisticated yet intuitive platform and process that finally allowed their Integrated Evidence Plan to become what it was always meant to be: a powerful engine for strategic decision-making and value creation across their diverse portfolio.